Literature DB >> 35322386

Methods for CRISPR-Cas as Ribonucleoprotein Complex Delivery In Vivo.

Alesya G Bykonya1, Alexander V Lavrov2, Svetlana A Smirnikhina2.   

Abstract

The efficient delivery of CRISPR-Cas components is still a key and unsolved problem. CRISPR-Cas delivery in the form of a Cas protein+sgRNA (ribonucleoprotein complex, RNP complex), has proven to be extremely effective, since it allows to increase on-target activity, while reducing nonspecific activity. The key point for in vivo genome editing is the direct delivery of artificial nucleases and donor DNA molecules into the somatic cells of an adult organism. At the same time, control of the dose of artificial nucleases is impossible, which affects the efficiency of genome editing in the affected cells. Poor delivery efficiency and low editing efficacy reduce the overall potency of the in vivo genome editing process. Here we review how this problem is currently being solved in scientific works and what types of in vivo delivery methods of Cas9/sgRNA RNPs have been developed.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CRISPR; Cas9; In vivo; Nanoparticles; RNP; Ribonucleoprotein complex

Year:  2022        PMID: 35322386     DOI: 10.1007/s12033-022-00479-z

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  108 in total

1.  Identification of genes that are associated with DNA repeats in prokaryotes.

Authors:  Ruud Jansen; Jan D A van Embden; Wim Gaastra; Leo M Schouls
Journal:  Mol Microbiol       Date:  2002-03       Impact factor: 3.501

2.  Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements.

Authors:  Francisco J M Mojica; César Díez-Villaseñor; Jesús García-Martínez; Elena Soria
Journal:  J Mol Evol       Date:  2005-02       Impact factor: 2.395

3.  CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes.

Authors:  Alexis C Komor; Ahmed H Badran; David R Liu
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

Review 4.  Molecular mechanisms of CRISPR-Cas spacer acquisition.

Authors:  Jon McGinn; Luciano A Marraffini
Journal:  Nat Rev Microbiol       Date:  2019-01       Impact factor: 60.633

5.  Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria.

Authors:  Giedrius Gasiunas; Rodolphe Barrangou; Philippe Horvath; Virginijus Siksnys
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

6.  Applications of CRISPR technologies in research and beyond.

Authors:  Rodolphe Barrangou; Jennifer A Doudna
Journal:  Nat Biotechnol       Date:  2016-09-08       Impact factor: 54.908

7.  Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product.

Authors:  Y Ishino; H Shinagawa; K Makino; M Amemura; A Nakata
Journal:  J Bacteriol       Date:  1987-12       Impact factor: 3.490

8.  A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.

Authors:  Martin Jinek; Krzysztof Chylinski; Ines Fonfara; Michael Hauer; Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2012-06-28       Impact factor: 47.728

9.  Cas9 specifies functional viral targets during CRISPR-Cas adaptation.

Authors:  Robert Heler; Poulami Samai; Joshua W Modell; Catherine Weiner; Gregory W Goldberg; David Bikard; Luciano A Marraffini
Journal:  Nature       Date:  2015-02-18       Impact factor: 49.962

10.  Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents.

Authors:  Xue Gao; Yong Tao; Veronica Lamas; Mingqian Huang; Wei-Hsi Yeh; Bifeng Pan; Yu-Juan Hu; Johnny H Hu; David B Thompson; Yilai Shu; Yamin Li; Hongyang Wang; Shiming Yang; Qiaobing Xu; Daniel B Polley; M Charles Liberman; Wei-Jia Kong; Jeffrey R Holt; Zheng-Yi Chen; David R Liu
Journal:  Nature       Date:  2017-12-20       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.